Clinical trial
Arsenic Trioxide, Cytarabine, and Idarubicin in Treating Patients With Acute…
NCT00093483 · Roswell Park Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00093483 |
|---|---|
| Title | Arsenic Trioxide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia |
| Official title | Arsenic Trioxide, High-Dose Cytarabine and Idarubicin Induction Therapy in Previously Untreated de Novo and Secondary Adult Acute Myeloid Leukemia Patients < 60 Years Old - A Phase I Study |
| Lead sponsor | Roswell Park Cancer Institute, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Biological, Drug |
| Interventions | filgrastim, arsenic trioxide, cytarabine, idarubicin |
| Enrollment | 61 |
| Start date | Apr 1, 2002 |
| Primary completion | Nov 1, 2009 |
| Completion | Dec 1, 2009 |
| First posted | Oct 8, 2004 |
| Last update posted | Jan 13, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: